GHP Investment Advisors Inc. Has $6.81 Million Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

GHP Investment Advisors Inc. grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 87,159 shares of the company’s stock after buying an additional 170 shares during the period. GHP Investment Advisors Inc. owned 0.18% of Prestige Consumer Healthcare worth $6,806,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in Prestige Consumer Healthcare by 3.2% in the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after purchasing an additional 8,533 shares during the period. Geode Capital Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Prestige Consumer Healthcare by 12.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after buying an additional 1,120 shares during the period. Avior Wealth Management LLC raised its stake in shares of Prestige Consumer Healthcare by 1,570.7% during the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock worth $668,000 after buying an additional 8,042 shares during the last quarter. Finally, Barclays PLC lifted its holdings in Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after buying an additional 71,730 shares during the period. Institutional investors own 99.95% of the company’s stock.

Insider Buying and Selling

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider William P’pool sold 8,987 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now owns 20,058 shares of the company’s stock, valued at $1,641,747.30. The trade was a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock worth $3,187,300 over the last ninety days. Company insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Stock Up 0.1 %

Shares of Prestige Consumer Healthcare stock opened at $75.90 on Thursday. Prestige Consumer Healthcare Inc. has a 1 year low of $60.00 and a 1 year high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The company has a market capitalization of $3.75 billion, a P/E ratio of 18.47, a price-to-earnings-growth ratio of 2.15 and a beta of 0.50. The business has a 50-day moving average of $79.29 and a two-hundred day moving average of $75.25.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. As a group, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on PBH shares. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. DA Davidson restated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.